Ligand Pharma (LGND) Tops Q2 EPS by 141c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $319.55 +2.42%
Revenue Growth %: +32.4%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
CRMT, More
Revenue Growth %: +32.4%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.81, $1.41 better than the analyst estimate of $0.40. Revenue for the quarter came in at $18.42 million versus the consensus estimate of $17 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- FactSet Research Systems (FDS) PT Raised to $253 at Jefferies
- SAS CEO van der Werff emerges as frontrunner for Air Canada top job - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
